Gelesis Holdings, Inc.: Business Overview, Financials & Competitive Analysis
Gelesis Holdings, Inc. scores 2/10 on the AskCyborg Cyborg Score (Challenged). Gelesis's innovative hydrogel technology was sound but failed to achieve market traction, ultimately leading to bankruptcy liquidation despite regulatory success. While the company achieved FDA approval for Plenity and demonstrated clinical efficacy, it faced severe commercialization challenges, resulting in liquidation in October 2023. The company's revenue of $12.1M (as.
What is Gelesis Holdings, Inc.'s industry? Gelesis Holdings, Inc. (gelesis.com) operates in GLP-1 & Obesity Drugs. AskCyborg classifies Gelesis Holdings, Inc. under GLP-1 & Obesity Drugs in its company registry.
Gelesis Holdings, Inc. was a Boston-based biotherapeutics company specializing in superabsorbent hydrogel therapies for weight management and gastrointestinal-related chronic diseases. The company's flagship product, ...
Cyborg Score thesis
Gelesis's innovative hydrogel technology was sound but failed to achieve market traction, ultimately leading to bankruptcy...
Read the full analyst-debate transcript →Get the Latest Gelesis Holdings, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeGelesis Holdings, Inc. Overview
Pro stress-test →Gelesis Holdings, Inc. was a Boston-based biotherapeutics company specializing in superabsorbent hydrogel therapies for weight management and gastrointestinal-related chronic diseases. The company's flagship product, Plenity (Gelesis100), received FDA clearance (April 2019) as a non-systemic, non-stimulant aid for weight management. However, Gelesis filed for Chapter 7 liquidation in October 2023.
Strategic Profile
Pro stress-test →Gelesis pioneered a biomimetic approach using naturally-derived hydrogels that mechanically expanded in the stomach to create satiety without systemic effects. The company pursued a diverse pipeline including Gelesis200 for Type 2 Diabetes and investigational candidates for NASH and functional constipation. Despite FDA approval and clinical validation, commercialization challenges and market headwinds led to financial distress.
Competitive Landscape
Pro stress-test →Gelesis competed in the obesity treatment space against pharmaceutical and medical device competitors including Vivus (oral GLP-1 agonists), NGM Biopharmaceuticals (metabolic disease focus), and oral weight-loss medications from major pharma. The rise of GLP-1 receptor agonists (semaglutide, tirzepatide) by Novo Nordisk and Eli Lilly created significant headwinds for mechanical/non-systemic approaches. Gelesis's mechanical-only mechanism and limited reimbursement differentiated but ultimately constrained its market opportunity.
Industry Context
Gelesis Holdings, Inc. operates in GLP-1 & Obesity Drugs.
Key facts
Founded: 2006 · Headquarters: Boston, MA, USA · Employees: 93 (as of 2023) · Revenue: $12.1M (trailing twelve months as of June 2023) · Market cap: $3.62M (as of August 2023)